Literature DB >> 20371486

Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass.

Robert Alcock1, Matthew G Cottingham, Christine S Rollier, Julie Furze, Samodh D De Costa, Marian Hanlon, Alexandra J Spencer, Jared D Honeycutt, David H Wyllie, Sarah C Gilbert, Migena Bregu, Adrian V S Hill.   

Abstract

Live recombinant viral vectors based on adenoviruses and poxviruses are among the most promising platforms for development of new vaccines against diseases such as malaria, tuberculosis, and HIV-AIDS. Vaccines based on live viruses must remain infectious to be effective, so therefore need continuous refrigeration to maintain stability and viability, a requirement that can be costly and difficult, especially in developing countries. The sugars sucrose and trehalose are commonly used as stabilizing agents and cryoprotectants for biological products. Here, we have exploited the ability of these sugars to vitrify on desiccation to develop a thermostabilization technique for live viral vaccine vectors. By slowly drying vaccines suspended in solutions of these disaccharide stabilizers onto a filter-like support membrane at ambient temperature, an ultrathin glass is deposited on the fibers of the inert matrix. Immobilization of two recombinant vaccine vectors-E1/E3-deleted human adenovirus type 5 and modified vaccinia virus Ankara-in this glass on the membranes enabled complete recovery of viral titer and immunogenicity after storage at up to 45 degrees C for 6 months and even longer with minimal losses. Furthermore, the membrane carrying the stabilized vaccine can be incorporated into a holder attached to a syringe for almost simultaneous reconstitution and injection at point of use. The technology may potentially be developed for the deployment of viral vector-based biopharmaceuticals in resource-poor settings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371486     DOI: 10.1126/scitranslmed.3000490

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  55 in total

Review 1.  Oral delivery of biologics using drug-device combinations.

Authors:  Ester Caffarel-Salvador; Alex Abramson; Robert Langer; Giovanni Traverso
Journal:  Curr Opin Pharmacol       Date:  2017-08-02       Impact factor: 5.547

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  A protective bivalent vaccine against Rift Valley fever and bluetongue.

Authors:  Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Julio Benavides; Aitor Nogales; Rafael Blasco; Alejandro Brun; Javier Ortego
Journal:  NPJ Vaccines       Date:  2020-07-30       Impact factor: 7.344

4.  Stability of influenza vaccine coated onto microneedles.

Authors:  Hyo-Jick Choi; Dae-Goon Yoo; Brian J Bondy; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Biomaterials       Date:  2012-02-21       Impact factor: 12.479

5.  Advancing microwave technology for dehydration processing of biologics.

Authors:  Stephanie L Cellemme; Matthew Van Vorst; Elisha Paramore; Gloria D Elliott
Journal:  Biopreserv Biobank       Date:  2013-10       Impact factor: 2.300

6.  Tailoring Trehalose for Biomedical and Biotechnological Applications.

Authors:  Mara K O'Neill; Brent F Piligian; Claire D Olson; Peter J Woodruff; Benjamin M Swarts
Journal:  Pure Appl Chem       Date:  2017-01-11       Impact factor: 2.453

Review 7.  T-cell-inducing vaccines - what's the future.

Authors:  Sarah C Gilbert
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

8.  Micro-fractional epidermal powder delivery for improved skin vaccination.

Authors:  Xinyuan Chen; Garuna Kositratna; Chang Zhou; Dieter Manstein; Mei X Wu
Journal:  J Control Release       Date:  2014-08-15       Impact factor: 9.776

9.  Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions.

Authors:  Guangchuan Wang; Rui-Yuan Cao; Rong Chen; Lijuan Mo; Jian-Feng Han; Xiaoyu Wang; Xurong Xu; Tao Jiang; Yong-Qiang Deng; Ke Lyu; Shun-Ya Zhu; E-De Qin; Ruikang Tang; Cheng-Feng Qin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

10.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.